36404-88-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-3-pyridinecarboxaldehyde is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those with potential therapeutic applications. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Organic Synthesis:
2-Chloro-3-pyridinecarboxaldehyde is used as a starting material for the preparation of 5-azaindoles through the Hemetsberger-Knittel reaction. This reaction involves the thermal decomposition of alkenyl azides, leading to the formation of 5-azaindole derivatives. These compounds have potential applications in various fields, including pharmaceuticals and materials science.
Used as Azaindazole Intermediate:
2-Chloro-3-pyridinecarboxaldehyde is utilized as an intermediate in the synthesis of azaindazole compounds. Azaindazoles are a class of heterocyclic compounds with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science. The unique properties of azaindazoles make them valuable building blocks for the development of new molecules with specific functions and activities.

InChI:InChI=1/C6H4ClNO/c7-6-5(4-9)2-1-3-8-6/h1-4H

Upstream product

• 109-09-1 2-chloropyridine 
• 2591-86-8 N-Formylpiperidine 
• 109-94-4 formic acid ethyl ester 
• 73583-37-6 2-chloro-4-bromopyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 2942-59-8 2-chloronicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 52200-48-3 3-bromo-2-chloropyridine 
• 591-50-4 iodobenzene 
• 7226-23-5 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
• 108-18-9 diisopropylamine 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 

Downstream Products

• 61856-52-8 3-formyl-pyridine-2(1H)-thione 
• 142274-26-8 (3-formyl-pyridin-2-ylsulphanyl)-propionic acid methyl ester 
• 71255-09-9 2-methoxynicotinaldehyde 
• 133001-41-9 2-Chloro-6'-methyl-2'-[4-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-phenyl]-5'-(pyridin-2-ylcarbamoyl)-1',4'-dihydro-[3,4']bipyridinyl-3'-carboxylic acid ethyl ester 
• 36404-89-4 2-oxo-1,2-dihydro-pyridine-3-carbaldehyde 
• 116854-97-8 2-hydrazinopyridine-3-aldehyde azine 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 232602-24-3 2-benzylpyridine-3-carbaldehyde 
• 494841-80-4 2-chloro-3-{(E)-[2-(4S,5S)-4-methoxymethyl-5-(4-methylthiophenyl)-4,5-dihydro-1,3-oxazol-2-yl]vinyl}pyridine 
• 852063-32-2 ethyl 4-(2-chloropyridin-3-yl)-4-oxobutyrate 
• 852063-33-3 ethyl 4-oxo-4-(2-(benzylseleno)pyridin-3-yl)butyrate 
• 494841-87-1 tert-butyl (3S)-3-{2-[4-methoxy-2-(4-methoxy-benzyloxymethyl)benzoyl]-3-pyridinyl}-3-(2,3-dihydro-1-benzofuran-6-yl)propanoate 
• 180748-12-3 7,8-Diphenyl-9-thia-1,6-diaza-benzocycloheptene 
• 180748-13-4 8-Phenyl-7-p-tolyl-9-thia-1,6-diaza-benzocycloheptene 

Relevant academic research and scientific papers

Synthesis of a 1,8-napththyridin-5-one derivative via an intramolecular 1,3-dipolar cycloaddition reaction

Synthesis of a 1,8-naphthyridin-5-one derivative [(5,6,7,8-tetrahydro-(3-chloro-6-hydroxymethyl-8-methyl)-1,8-naphthyri din-5-one (9)] is described starting from 2-chloronicotinic acid using an intramolecular 1,3-dipolar cycloaddition reaction as the key step.

Method for preparing aldehyde and acid by electrochemical dehydrochlorination of polychloromethylpyridine derivatives

The invention discloses a method for preparing aldehyde and an acid by electrochemical dechlorination of a polychloromethylpyridine derivative, the method comprises the following steps: dissolving thepolychloromethylpyridine derivative in an acetic acid and acetate- containing buffer solution to obtain an electrolytic reaction solution; taking the electrolytic reaction solution as a cathode liquid, performing electrolytic reduction dechlorination reaction at a cathode, and hydrolyzing in the solution to obtain a polychlorinated pyridylaldehyde or acid derivative. The polychloromethylpyridinederivative is shown in formula (I), and the product polychlorinated pyridylaldehyde or acid derivative is shown in formula (II): in the formula (I), m is 0, 1, 2, 3 or 4, n is 0 or 1, and R' is an easy-to-oxidize or easy-to-hydrolyze substituent. The m and the R' in the formula (II) are same as that in the formula (I), R is H or OH, no waste acid is generated in the preparation process, the easy-to-oxidize or easy-to-hydrolyze substituent contained in the polychloromethylpyridine derivative and carbon-chlorine bonds on pyridine rings are not affected, and the recovery conversion rate is high.

FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

A 2 - chloro - 3 - pyridine formaldehyde synthetic method (by machine translation)

The invention discloses a 2 - chloro - 3 - pyridyl aldehyde synthesis method, the method to 2 - chloro - 3 - methyl pyridine as raw materials, passes through chlorine chlorinated, ester hydrolysis, oxidation three-step to obtain 2 - chloro - 3 - pyridine formaldehyde product. The method of the invention mild reaction conditions, high yield, low cost, product purity up to 98% or more, and has a good industrial application prospect. (by machine translation)

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists

N-Benzyl substitution of phenethylamine 5-HT2A receptor agonists has dramatic effects on binding affinity, receptor selectivity and agonist activity. In this paper we examine how affinity for the 5-HT2A/2C receptors are influenced by N-benzyl substitution of 4-bromo-2,5-dimethoxyphenethylamine derivatives. Special attention is given to the 2′ and 3′-position of the N-benzyl as such compounds are known to be very potent. We found that substitutions in these positions are generally well tolerated. The 2′-position was further examined using a range of substituents to probe the hydrogen bonding requirements for optimal affinity and selectivity, and it was found that small changes in the ligands in this area had a profound effect on their affinities. Furthermore, two ligands that lack a 2′-benzyl substituent were also found to have high affinity contradicting previous held notions. Several high-affinity ligands were identified and assayed for functional activity at the 5-HT2A and 5-HT2C receptor, and they were generally found to be less efficacious agonists than previously reported N-benzyl phenethylamines.

Novel aromatic fluoroolefins via fluoro-Julia-Kocienski olefination

Fluoroolefins, which play an increasingly important role as peptide mimics in pharmaceuticals and as crop protection agents, are generated using a fluoro-Julia-Kocienski olefination. Their preparation can easily be accomplished using a Mitsunobu reaction and subsequent oxidation to generate the required benzothiazolyl sulfones. The key step of this process was the electrophilic -fluorination of the sulfone with N-fluorobenzenesulfonimide. The last stage of the successful synthesis of the fluoroolefins was the modified Julia-Kocienski olefination under basic conditions. Further functionalization was followed with the application of a Suzuki reaction. Georg Thieme Verlag Stuttgart.

Efficient route to medium-ring benzo- and azabenzo-lactones

The synthesis of precursors of medium-ring benzo- and azabenzo-lactones is performed efficiently from simple ortho-halo aryl and heteroaryl aldehydes. Copyright Taylor & Francis Group, LLC.

A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K + channel

A series of compounds based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl} -6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol ((-)-8b), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K+ channel. From these studies, 101 was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K+channel. Furthermore, 101 showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.

Method of Treating Pathological Blushing

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.